Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Multimodal imaging of foveal neovascularisation in diabetic retinopathy.

Bansal A, Shankar M, Multani P, Luthra S.

Clin Exp Optom. 2019 Jul;102(4):440-441. doi: 10.1111/cxo.12857. Epub 2018 Dec 5. No abstract available.

PMID:
30520107
2.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
3.

Community outreach: An indicator for assessment of prevalence of amblyopia.

Magdalene D, Bhattacharjee H, Choudhury M, Multani PK, Singh A, Deshmukh S, Gupta K.

Indian J Ophthalmol. 2018 Jul;66(7):940-944. doi: 10.4103/ijo.IJO_1335_17.

4.

Changing uveitis patterns in South India - Comparison between two decades.

Biswas J, Kharel Sitaula R, Multani P.

Indian J Ophthalmol. 2018 Apr;66(4):524-527. doi: 10.4103/ijo.IJO_851_17.

5.

Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.

Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P.

J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.

PMID:
29118225
6.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA.

Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.

7.

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL.

J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.

8.

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK.

NPJ Precis Oncol. 2017 Mar 20;1(1):5. doi: 10.1038/s41698-017-0009-y. eCollection 2017.

9.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

10.

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.

Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J, Yan S, Wei G, Oliver JW, Patel R, Multani P, Ladanyi M, Drilon A.

Clin Cancer Res. 2017 Jun 15;23(12):2981-2990. doi: 10.1158/1078-0432.CCR-16-1887. Epub 2016 Dec 23.

11.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL.

Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.

12.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S.

Br J Cancer. 2015 Dec 22;113(12):1730-4. doi: 10.1038/bjc.2015.401. Epub 2015 Dec 3.

13.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

14.

Should the ovary always be conserved in torsion? A tertiary care institute experience.

Parelkar SV, Mundada D, Sanghvi BV, Joshi PB, Oak SN, Kapadnis SP, Shetty S, Athawale H, Multani P.

J Pediatr Surg. 2014 Mar;49(3):465-8. doi: 10.1016/j.jpedsurg.2013.11.055. Epub 2013 Nov 19.

PMID:
24650479
15.

Trocarless laparoscopic pyloromyotomy with conventional instruments: Our experience.

Parelkar SV, Multani PV, Sanghvi BV, Shetty SR, Athawale HR, Kapadnis SP, Mundada DD, Oak SN.

J Minim Access Surg. 2013 Oct;9(4):159-62. doi: 10.4103/0972-9941.118831.

16.

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, Pelus LM, Desponts C, Chen YB, Rezner B, Armand P, Koreth J, Glotzbecker B, Ho VT, Alyea E, Isom M, Kao G, Armant M, Silberstein L, Hu P, Soiffer RJ, Scadden DT, Ritz J, Goessling W, North TE, Mendlein J, Ballen K, Zon LI, Antin JH, Shoemaker DD.

Blood. 2013 Oct 24;122(17):3074-81. doi: 10.1182/blood-2013-05-503177. Epub 2013 Aug 30.

17.

VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Multani PK, Hodge R, Estévez MA, Abel T, Kung H, Alter M, Brookshire B, Lucki I, Nall AH, Talbot K, Doyle GA, Lohoff FW.

Neuroscience. 2013 Mar 1;232:32-44. doi: 10.1016/j.neuroscience.2012.11.023. Epub 2012 Nov 29.

18.

Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European Americans.

Multani PK, Clarke TK, Narasimhan S, Ambrose-Lanci L, Kampman KM, Pettinati HM, Oslin DW, O'Brien CP, Berrettini WH, Lohoff FW.

Neurosci Lett. 2012 Nov 30;531(1):46-51. doi: 10.1016/j.neulet.2012.09.014. Epub 2012 Sep 20.

19.

Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.

Narasimhan S, Aquino TD, Multani PK, Rickels K, Lohoff FW.

Psychiatry Res. 2012 Jun 30;198(1):112-5. doi: 10.1016/j.psychres.2011.12.034. Epub 2012 Mar 13.

PMID:
22417933
20.

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.

Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K.

Pharmacogenomics J. 2013 Feb;13(1):21-6. doi: 10.1038/tpj.2011.47. Epub 2011 Oct 18.

PMID:
22006095
21.

Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death.

Chang KH, Multani PS, Sun KH, Vincent F, de Pablo Y, Ghosh S, Gupta R, Lee HP, Lee HG, Smith MA, Shah K.

Mol Biol Cell. 2011 May;22(9):1452-62. doi: 10.1091/mbc.E10-07-0654. Epub 2011 Mar 9.

22.

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI.

Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23.

PMID:
19108889
23.

Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.

Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI.

Leuk Res. 2009 Jun;33(6):769-74. doi: 10.1016/j.leukres.2008.09.020. Epub 2008 Oct 30.

PMID:
18976810
24.

Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.

Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC.

Biotechnol Annu Rev. 2004;10:265-95. Review.

PMID:
15504711
25.

Rituximab.

Multani P, White CA.

Cancer Chemother Biol Response Modif. 2003;21:235-58. Review. No abstract available.

PMID:
15338748
26.

No clinical evidence for CD4+ cell depletion caused by rituximab.

Saville MW, Benyunes MC, Multani PS.

Blood. 2003 Jul 1;102(1):408; author reply 408-9. No abstract available.

27.

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS.

J Clin Oncol. 2003 Apr 1;21(7):1263-70.

PMID:
12663713
28.

Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.

Nabhan C, Peterson LA, Kent SA, Tallman MS, Dewald G, Multani P, Gordon LI.

Leuk Lymphoma. 2002 Nov;43(11):2145-9.

PMID:
12539741
29.

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.

Multani P.

Int J Hematol. 2002 Dec;76(5):401-10. Review.

PMID:
12512834
31.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA.

J Clin Oncol. 2002 Aug 1;20(15):3262-9.

PMID:
12149300
32.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA.

Blood. 2002 Jun 15;99(12):4336-42.

33.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.

J Clin Oncol. 2002 May 15;20(10):2453-63.

PMID:
12011122
34.

Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.

Grillo-López AJ, Dallaire BK, McClure A, Weaver R, Varns C, Wei A, Allen R, Lee D, Shen D, Leonard J, Multani P, White CA.

Curr Pharm Biotechnol. 2001 Dec;2(4):301-11. Review.

PMID:
11762412
35.

Non-Hodgkin's lymphoma: review of conventional treatments.

Multani P, White CA, Grillo-López A.

Curr Pharm Biotechnol. 2001 Dec;2(4):279-91. Review.

PMID:
11762410
36.

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.

Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.

Biol Blood Marrow Transplant. 2000;6(3A):309-20.

PMID:
10905768
37.

Melanoma.

Haluska FG, Multani PS.

Cancer Chemother Biol Response Modif. 1999;18:470-88. Review.

PMID:
10800498
38.

Antimetabolites.

Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA, Allegra CJ, Johnston PG.

Cancer Chemother Biol Response Modif. 1999;18:1-38. Review. No abstract available.

PMID:
10800475
39.

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.

Toh HC, McAfee SL, Sackstein R, Multani P, Cox BF, Garcia-Carbonero R, Colby C, Spitzer TR.

Bone Marrow Transplant. 2000 Jan;25(1):19-24.

40.

A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM.

Clin Cancer Res. 1999 Sep;5(9):2392-8.

41.
42.

Monoclonal antibody-based therapies for hematologic malignancies.

Multani PS, Grossbard ML.

J Clin Oncol. 1998 Nov;16(11):3691-710. Review.

PMID:
9817291
43.
44.

Staging Laparotomy in the Management of Hodgkin's Disease: Is It Still Necessary?

Multani PS, Grossbard ML.

Oncologist. 1996;1(1 & 2):41-55.

45.

Neocortical dendritic pathology in human partial epilepsy: a quantitative Golgi study.

Multani P, Myers RH, Blume HW, Schomer DL, Sotrel A.

Epilepsia. 1994 Jul-Aug;35(4):728-36.

PMID:
7521835

Supplemental Content

Loading ...
Support Center